-
-
-
-
-
-
-
Krystal Biotech (KRYS) Submits BLA to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
-
-
-
-
-
-
-
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
-
-
-
-
-
-
-
Krystal Biotech (KRYS) Submits IND Application for KB105
-
-
-
-
-
-
-
Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters
-
-
-
-
-
-
-
Krystal Biotech to Present at Evercore ISI HealthCONx
-
-
-
-
-
-
-
Krystal Biotech (KRYS) Granted FDA Fast Track Designation for KB103 for Treatment of Dystrophic Epidermolysis Bullosa
-
-
-
-
-
-
-
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

